We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+18.42%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.07B
AUM Growth
+$166M
Cap. Flow
+$47.2M
Cap. Flow %
4.41%
Top 10 Hldgs %
29.4%
Holding
105
New
13
Increased
43
Reduced
32
Closed
11

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$17.2M
2
DOCS icon
Doximity
DOCS
+$13.3M
3
AMGN icon
Amgen
AMGN
+$11.4M
4
NUVL
Nuvalent
NUVL
+$10.9M
5
VERA icon
Vera Therapeutics
VERA
+$10.3M

Top Sells

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$19M
2
CAH icon
Cardinal Health
CAH
+$14.8M
3
ABT icon
Abbott
ABT
+$13.2M
4
CYTK icon
Cytokinetics
CYTK
+$13.1M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$11.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRUS
101
DELISTED
Merus
MRUS
– –
-53,500
Closed -$5.04M
RARE icon
102
Ultragenyx Pharmaceutical
RARE
$2.65B
– –
-119,400
Closed -$3.59M
TECH icon
103
Bio-Techne
TECH
$11.3B
– –
-15,000
Closed -$834K
UHS icon
104
Universal Health Services
UHS
$10.2B
– –
-12,000
Closed -$2.45M
UTHR icon
105
United Therapeutics
UTHR
$22.7B
– –
-8,000
Closed -$3.35M
1 2 3 4
5

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2025 Portfolio in Review

As of Q4 2025, Rhenman & Partners Asset Management held 105 positions worth $1.07B, up 18% from $904M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management deployed $47.2M of net new capital in Q4 2025, opening 13 new positions and adding to 43 existing holdings. Its largest new stake was Amgen: 36,000 shares worth $11.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Cytokinetics, an estimated $13.1M trimmed.

  • Rhenman & Partners Asset Management's largest Q4 2025 buy was Amgen: 36,000 shares worth $11.8M.
  • Rhenman & Partners Asset Management added most to Regeneron Pharmaceuticals in Q4 2025, an estimated $17.2M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2025 reduction was Cytokinetics, cutting an estimated $13.1M.
  • Rhenman & Partners Asset Management fully exited Exact Sciences in Q4 2025, selling an estimated $19M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $1.07B portfolio in Q4 2025.
  • Rhenman & Partners Asset Management opened 13 new positions and closed 11 in Q4 2025.
  • Rhenman & Partners Asset Management's portfolio value rose 18% quarter-over-quarter to $1.07B.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.